More Arovella Therapeutics Limited news
Arovella Therapeutics LimitedASX: ALA

SUDA announces update on ZolpiMist in USA and Canada

Jun 15, 2018 at 1:39 AM EDT · Issued by Arovella Therapeutics Limited

Filed with ASX · Jun 15, 2018 at 1:39 AM EDT · 2 pages · English

On 6ix: 6ix.com/news/suda-announces-update-on-zolpimist-in-usa-and-canada

Arovella Therapeutics Limited on 6ix

Story so far

  • SUDA Meeting For Zolpimist Into EuropeMay 25, 2017
  • SUDA Enters Licensing Agreement For ZolpiMist in ChinaNov 9, 2016

Earlier from Arovella Therapeutics

  • SUDA expands dialogue with World Health OrganisationMay 7, 2018
  • HC Berlin Pharma UpdateMay 1, 2018
  • SUDA Completes Divestment of SubsidiaryMar 7, 2018
  • Divestment Of Non-Core SubsidiaryFeb 26, 2018
  • New Analyst ReportFeb 15, 2018

Later from Arovella Therapeutics

  • SUDA Expands Patent Coverage For SildenafilJun 17, 2018
  • Shareholder UpdateJun 20, 2018
  • Settlement with HC Berlin Pharma and Rights IssueJul 1, 2018
  • Prospectus for a Renounceable Pro Rata OfferJul 1, 2018
  • Anagrelide UpdateJul 11, 2018
All Arovella Therapeutics news releases↗

Follow Arovella Therapeutics into a list and get an email when it puts out news.

Follow Arovella Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer